Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1139–1144. doi: 10.1038/sj.bjc.6690181

Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations

S Nakagawa 1, H Yoshikawa 1, H Jimbo 1, T Onda 1, T Yasugi 1, K Matsumoto 1, N Kino 1, K Kawana 1, T Kozuka 2, K Nakagawa 2, M Aoki 2, Y Taketani 1
PMCID: PMC2362249  PMID: 10098748

Abstract

The p53 mutation has been found only in 0–6% of cervical carcinomas. In light of recent studies demonstrating that mutation of p53 gene was found in over 20% of the patients with vulvar carcinoma a disease of elderly women and a known human papillomavirus (HPV)-related malignancy, we analysed mutation of the p53 gene in 46 women with cervical carcinomas at the age of 60 or more (mean; 71 years, range; 60–96 years). The presence of HPV and its type were analysed by polymerase chain reaction (PCR)-based assay using the consensus primers for L1 region. Mutation of the p53 gene was analysed by PCR-based single-strand conformation polymorphism and DNA sequencing technique. Point mutation of the p53 gene was detected in 5 out of 46 (11%) cervical carcinomas: 1 of 17 (6%) samples associated with high-risk HPVs (HPV 16 and HPV 18) and 4 of 27 samples (15%) with intermediate-risk HPVs (P = 0.36) whereas no mutation was found in 2 HPV negative cases. The mutated residues resided in the selective sequence known as a DNA-binding domain. The immunohistochemistry revealed the overexpression in cancer tissues positive for p53 mutation. All of the observed mutations of the p53 gene were transition type, suggesting that the mutation may be caused by endogenous mutagenesis. Although falling short of statistical significance reduces the strength of the conclusion, data presented here imply that p53 gene mutation, particularly along with intermediate-risk HPV types, may constitute one pathogenetic factor in cervical carcinoma affecting elderly women. © 1999 Cancer Research Campaign

Keywords: human papillomavirus, p53 mutation, cervical carcinoma, elderly women

Full Text

The Full Text of this article is available as a PDF (259.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994 Jul 15;265(5170):346–355. doi: 10.1126/science.8023157. [DOI] [PubMed] [Google Scholar]
  2. Choo K. B., Chong K. Y. Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. Virology. 1993 Apr;193(2):1042–1046. doi: 10.1006/viro.1993.1224. [DOI] [PubMed] [Google Scholar]
  3. Crook T., Vousden K. H. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 1992 Nov;11(11):3935–3940. doi: 10.1002/j.1460-2075.1992.tb05487.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fujinaga Y., Shimada M., Okazawa K., Fukushima M., Kato I., Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol. 1991 May;72(Pt 5):1039–1044. doi: 10.1099/0022-1317-72-5-1039. [DOI] [PubMed] [Google Scholar]
  5. Fujita M., Inoue M., Tanizawa O., Iwamoto S., Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res. 1992 Oct 1;52(19):5323–5328. [PubMed] [Google Scholar]
  6. Helland A., Holm R., Kristensen G., Kaern J., Karlsen F., Trope C., Nesland J. M., Børresen A. L. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol. 1993 Oct;171(2):105–114. doi: 10.1002/path.1711710207. [DOI] [PubMed] [Google Scholar]
  7. Huibregtse J. M., Scheffner M., Howley P. M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol. 1993 Feb;13(2):775–784. doi: 10.1128/mcb.13.2.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kanda T., Watanabe S., Yoshiike K. Immortalization of primary rat cells by human papillomavirus type 16 subgenomic DNA fragments controlled by the SV40 promoter. Virology. 1988 Jul;165(1):321–325. doi: 10.1016/0042-6822(88)90694-0. [DOI] [PubMed] [Google Scholar]
  9. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491–7495. doi: 10.1073/pnas.89.16.7491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lechner M. S., Laimins L. A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol. 1994 Jul;68(7):4262–4273. doi: 10.1128/jvi.68.7.4262-4273.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lee Y. Y., Wilczynski S. P., Chumakov A., Chih D., Koeffler H. P. Carcinoma of the vulva: HPV and p53 mutations. Oncogene. 1994 Jun;9(6):1655–1659. [PubMed] [Google Scholar]
  12. Lorincz A. T., Reid R., Jenson A. B., Greenberg M. D., Lancaster W., Kurman R. J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992 Mar;79(3):328–337. doi: 10.1097/00006250-199203000-00002. [DOI] [PubMed] [Google Scholar]
  13. Milde-Langosch K., Albrecht K., Joram S., Schlechte H., Giessing M., Löning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer. 1995 Nov 27;63(5):639–645. doi: 10.1002/ijc.2910630507. [DOI] [PubMed] [Google Scholar]
  14. Miwa K., Miyamoto S., Kato H., Imamura T., Nishida M., Yoshikawa Y., Nagata Y., Wake N. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer. 1995 Feb;71(2):219–226. doi: 10.1038/bjc.1995.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Münger K., Phelps W. C., Bubb V., Howley P. M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989 Oct;63(10):4417–4421. doi: 10.1128/jvi.63.10.4417-4421.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Münger K., Werness B. A., Dyson N., Phelps W. C., Harlow E., Howley P. M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989 Dec 20;8(13):4099–4105. doi: 10.1002/j.1460-2075.1989.tb08594.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Naito M., Satake M., Sakai E., Hirano Y., Tsuchida N., Kanzaki H., Ito Y., Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res. 1992 Oct;83(10):1030–1036. doi: 10.1111/j.1349-7006.1992.tb02717.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nakagawa S., Watanabe S., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology. 1995 Oct 1;212(2):535–542. doi: 10.1006/viro.1995.1511. [DOI] [PubMed] [Google Scholar]
  19. Nakagawa S., Yoshikawa H., Onda T., Kawana T., Iwamoto A., Taketani Y. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer. 1996 Nov 1;78(9):1935–1941. [PubMed] [Google Scholar]
  20. Nevins J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992 Oct 16;258(5081):424–429. doi: 10.1126/science.1411535. [DOI] [PubMed] [Google Scholar]
  21. Paquette R. L., Lee Y. Y., Wilczynski S. P., Karmakar A., Kizaki M., Miller C. W., Koeffler H. P. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer. 1993 Aug 15;72(4):1272–1280. doi: 10.1002/1097-0142(19930815)72:4<1272::aid-cncr2820720420>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  22. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8. [DOI] [PubMed] [Google Scholar]
  23. Snijders P. J., van den Brule A. J., Schrijnemakers H. F., Snow G., Meijer C. J., Walboomers J. M. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990 Jan;71(Pt 1):173–181. doi: 10.1099/0022-1317-71-1-173. [DOI] [PubMed] [Google Scholar]
  24. Storey A., Pim D., Murray A., Osborn K., Banks L., Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 1988 Jun;7(6):1815–1820. doi: 10.1002/j.1460-2075.1988.tb03013.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yoshikawa H., Kawana T., Kitagawa K., Mizuno M., Yoshikura H., Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res. 1991 May;82(5):524–531. doi: 10.1111/j.1349-7006.1991.tb01882.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES